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Summary Recombinant single-chain fragments (scFv) of the murine anti-MUC1 monoclonal antibody C595 have been produced using the
original hybridoma cells as a source of variable heavy (VH)- and variable light(VL)-chain-encoding antibody genes. The use of the polymerase
chain reaction (PCR), bacteriophage (phage) display technology and gene expression systems in E. colihas led to the production of soluble
C595 scFv. The scFv has been purified from the bacterial supernatant by peptide epitope affinity chromatography, leading to the recovery of
immunoreactive C595 scFv, which was similar in activity to the C595 parent antibody. Analysis by DNA sequencing, SDS-PAGE and Western
blotting has demonstrated the integrity of the scFv, while ELISA, FACScan analysis, fluorescence quenching, quantitative immunoreactivity
experiments and immunohistochemistry confirm that the activity of the scFv compares favourably with that of the parent antibody. The
retention of binding activity to MUC1 antigen on human bladder and breast carcinoma tissue specimens illustrates the potential application of
this novel product as an immunodiagnostic and immunotherapeutic reagent.
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MUCI mucins are highly glycosylated glycoproteins expressed on
the luminal surfaces of glandular epithelia (Gendler et al, 1991;
Price and Tendler, 1993). Apart from their major physiological
functions as protective agents and biological lubricants, they are
frequently elevated and/or altered in cancer and thus have the
potential to be tumour markers. In breast carcinomas, forexample,
their expression is frequently up-regulated and they may be
secreted into the circulation. Determination ofthe levels ofMUCI
antigen in the blood has been exploited as a measure of tumour
burden, and changing levels reflect the response to therapy
(Berruti et al, 1994; Martoni et al, 1995). Novel determinants on
mucins from malignant cells have been evoked as targets for
immune manipulation in the cancer patient as they may induce
both humoral (Rughetti etal, 1993; Kotera et al, 1994) and cellular
(Jerome et al, 1991; Domenech et al, 1995) responses.
The MUCl glycoprotein is a complex molecule with a protein
core containing a large domain of variable numbers of a highly
conserved 20 amino acid repeat sequence (PDTRPAPGSTAP-
PAHGVTSA) (Gendler et al, 1988). Many murine antibodies
reactive with the MUCI mucin have now been produced by immu-
nization with diverse materials, including milk-fat globule
membranes, tumour cells and isolated mucin preparations. Most, if
not all, anti-MUCI antibodies reactive with the protein core define
epitopes of 3, 4 or 5 amino acids within the hydrophilic region
APDTRPAP ofthe 20 amino acid repeat. The antibody C595 is one
such antibody. This antibodyhas been proved tobe areagentofclin-
ical use. It has been used in immunoassays for the measurement of
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circulating mucin in breast cancer patients (Price et al, 1992; Dixon
et al, 1993) and has been used for in vivo diagnostic tests in the
identification ofmalignant ovarian tumours by immunoscintigraphy
(Symonds et al, 1992; Perkins et al, 1993). Also, bladder tumours
have been detected by gamma camera imaging following intra-
vesical administration of "'In-labelled C595 (Kunkler et al, 1995).
The present investigation was initiated to produce derivatives of
anti-MUCl mucin antibodies that would have the potential for use
in tumour targeting. Here, we describe the production of a recom-
binant antibody fragment based on the variable region of the anti-
MUC1 mucin monoclonal antibody C595. Detailed analyses ofthe
scFv confirm that its antigen recognition characteristics are similar
to those ofthe parent antibody so that further diagnostic and thera-
peutic applications may be considered.
MATERIALS AND METHODS
Monoclonal antibody production
Monoclonal antibody, C595 (IgG3, kappa lightchain), was prepared
by conventional hybridomatechnology (Kohlerand Milstein, 1975)
using spleen cells from a BALB/c mouse immunized against puri-
fiedMUCI urinary mucin (Price et al, 1990). The C595 monoclonal
antibody has the alternative designation NCRC-48.
mRNA extraction
C595 hybridoma cells (1 x 107) were harvested by centrifugation
(3000g for 5 min), the supematant removed by gentle aspiration
and the cellular pellet vortexed briefly. Total poly(A)+ mRNA was
extracted from the pellet using a Dynabeads mRNA Direct Kit
(Dynal, Oslo, Norway). The RNA extract was dissolved in 50 ,u
of sterile water, quantified and assessed for purity by absorbance
determination at 280 and 260 nm (Sambrook et al, 1989) and
stored at-20°C.
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scFv assembly
Hybridoma mRNA served as the template to construct C595 scFv
using the Recombinant Phage Antibody System (RPAS;
Pharmacia, Uppsala, Sweden), incorporating many ofthe features
described by McCafferty et al (1990) and Winter and Milstein
(1991). Briefly, RPAS reagents were used to produce a cDNA
library from mRNA through reverse transcription with random
(N6) primers. Separate antibody VH- and VL-chain-encoding
regions were amplified by PCR from the cDNA library using VH_
and VL-specific oligonucleotide primers. Isolated, agarose gel-
purified VH- and VL-encoding DNA were spliced togetherby PCR
using primers designed to introduce a linking sequence between
the two gene segments and specific restriction sites atboth 5'(Sfil)
and 3' (Notl) ends of the spliced sequence. Restriction digestion
with SfiI and NotI endonucleases and agarose gel purification of
the digested linked product preceded ligation ofthis DNA into the
SfiI- and Notl-digested phagemid vector pCANTAB SE. This
vector was then used to transform competent TG1 E. coli cells
using a heat shock (42°C) transformation method (RPAS).
Transformed TG1 E. coli were then subjected to a phage rescue
protocol using the helper phage M13KO7, producing a recombi-
nant phage library (3 x 109 pfu) of C595 encoding VH_ and VL-
linked genes. This phage library wasused to infectHB2151 E. coli
to obtain clones able to produce soluble scFv as opposed to
displaying the scFv as a fusion product on the phage surface. A
colony of HB2151 cells was transferred from a minimal medium
plate and grown for 3 h at 37°C, with shaking at 250 r.p.m.
(RPAS). The phage library solution (1 g1 - approximately
1 x 106 pfu) was added to the cells incubated at 37°C with inter-
mittent shaking and the cells were streaked onto SOBAG-N plates
(SOBAG medium containing 100jg ml-' nalidixic acid; RPAS)
and incubated overnight at 30°C. Individual colonies were then
analysed by PCR to check for the presence of C595 VH_ and VL_
specific DNA inserts.
Primer design
The primers used in the scFv assembly were provided in the RPAS
mouse scFv module. Primers used in sequencing reactions and in
PCR analyses were prepared using an ABI 394 DNA synthesizer
(ABI, Foster City, CA, USA) at the Biopolymer Synthesis and
Analysis Unit (BSAU), Department of Biochemistry, University
of Nottingham, UK. The primers denoted S1 (5'-CAACGT-
GAAAAAATTATTATTCGC-3') and S6 (5'-GTAAATGAATTlTT-
CTGTATGAGG-3') were based on the pCANTAB SE vector
sequence. The primers denoted II (5'-TGTGCAAGAGATCGG-
GATGGTTAC-3') and 12 (5'-ACTACTCCACTGCTGGCAG-
TAATA-3') were based on the complementarity-determining
region (CDR)-3-encoding DNA sequences ofthe C595 heavy and
light chains respectively (Denton et al, 1995).
PCR analysis
A non-suppressor strain ofE. coli (HB2151) was infected with the
recombinant phage library and infected clones were anlaysed by
PCR for the incorporation of C595 scFv-encoding DNA using
C595 heavy- and light-chain-specific primers II and I2 and the
vector-specific primers S1 and S6. PCRs were set up using phage-
infected HB2151 E. coli colonies as a source of C595 scFv-
specific DNA. PCRs were performed in 100,l1 aliquots using
50 pM of each primer per reaction on an OmniGene Thermal
Cycler Controller (Hybaid, Teddington, UK) and consisted of 30
cycles of94°C for45 s, 56°C for45 s and72°C for90 s,representing
denaturation, annealing and elongation temperatures respectively.
Agarose gel electrophoresis
Agarose gels (1%) were prepared by dissolving NuSieve agarose
(Flowgen, Sittingboume, UK) in TBE buffer (0.09 M Tris-borate,
0.002 M EDTA). Ethidium bromide (0.2 jig ml-') was incorpo-
rated into the gel before pouring. Samples were diluted with
DNA loading buffer, and electrophoresis was performed. DNA
was visualized using a Spectroline TM-312A Ultra Violet
Transilluminator, and photographs were recorded using a Polaroid
DS-34 Direct Screen Instant Camera.
scFv expression
Induction of scFv expression was achieved using the lacZ
promoter ofthe pCANTAB 5E vector by the addition ofisopropyl
beta-D-thiogalactopyranoside (IPTG) substrate into SB medium
supplemented with 100 jg ml-' ampicillin (Sambrook et al, 1989).
A total of800 ml ofsubstrate was added. Clone 31 was chosen for
scFv production on this scale, as preliminary SDS-PAGE and
Western blot analyses using 50 ml of substrate had identified this
clone as the highest expressor of scFv.
C595 scFv clone 31 purification
Recombinant C595 scFv clone 31 was recovered from the super-
natant ofthe bacterial broth, which was centrifuged at 48 000 g for
1 h. The supernatant was decanted through Whatman no. 1 filter
paper, sodium azide was added to 0.02% (w/v) and the supernatant
was processed through a 0.2-jm, 500-ml bottle filter unit (Costar,
High Wycombe, UK). The supernatant was then applied to a
peptide epitope affinity column consisting of Sepharose 4B
(Pharmacia) conjugated to the peptide APDTRPAPG (Price et al,
1991). This conjugate contains the epitope (RPAP) recognized by
the antibody C595, thus only immunoreactive scFv will bind to this
column. The column was washed by the addition of phosphate-
buffered saline (PBS) containing 0.02% (w/v) sodium azide and
then connected to a G25 Sephadex desalting column. Elution ofthe
bound scFv was performed by the application of 3 M sodium thio-
cyanate. Purified scFv concentrations intheeluent were determined
spectrophotometrically at 280 nm using the Beer-Lambert law.
Analysis of scFv clones by sodium dodecyl sulphate
(SDS) polyacrylamide gel electrophoresis (SDS-PAGE)
and Western blotting
Affinity-purified C595 scFvclone 31 samples werediluted 1:1 with
SDS loading buffer [bromophenol blue (0.05% w/v), sucrose (40%
w/v), EDTA (0.1 M, pH 8.0) and SDS (0.5% w/v)] and pretreated
by boiling for 5 min before loading. SDS-PAGE was performed
using a PhastSystem Separation and Control Unit (Pharmacia) in
conjunction with PhastGel precast gels (homogeneous acrylamide,
12.5% w/v). Silver staining was performed using the PhastGel
silver staining kit on the PhastSystem Development Unit. Western
blotting was achieved onto nitrocellulose membrane (Biorad,
Hemel HempsteAd, UK) using the PhastTransfer semi-dry
transfer kit and transfer buffer (25 mM Tris, 190 mm glycine in
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1:4 methanol-water). After transfer, the membrane was incubated
for 1 h in 0.1% casein (w/v) in PBS to block non-specific binding
sites. After four washes with PBS, the membrane was incubated
with a 1:1000 solution of anti-E-Tag/horseradish peroxidase
(HRPO) conjugate (Pharmacia) in PBS for 1 h. After four washes
with PBS, the blot was developed using 3-amino-9-ethylcarbazole
in 50 mm sodium acetate buffer pH 5.5, with the addition of
hydrogen peroxide at 5 ,l ml-' (3-AEC substrate).
DNA sequencing analysis
The clone containing C595-encoding DNA and expressing the
scFv as identified by Western blot (clone 31) was further analysed
through DNA sequencing. This clone was grown overnight and
plasmid (phagemid) DNA extracted using a Hybaid Recovery Kit
(Hybaid), essentially using protocols of plasmid minipreparation
as outlined in Sambrook et al (1989). Sequencing reactions were
performed on an ABI 373A DNA Sequencer (ABI) using the
PRISM DyeDeoxy Terminator Cycle Sequencing Kit (ABI) and
I1, 12, S1 and S6 primers.
Immunoreactivity by enzyme-linked immunosorbant
assay (ELISA)
Microtitre plates (96-well, flat bottomed, Falcon 3912; Becton
Dickinson, Oxford, UK) were coated with affinity-purified urinary
mucin (Price et al, 1990) or with branched chain polylysine conju-
gate containing multiple copies of the peptide CAPDTRPAPG
(Hudecz and Price, 1992) (added at 50 ,l per well at 10 jig ml-'
and incubated for 37°C for 18 h). A negative control antigen was
coated to the wells in the same manner. This consisted ofa MUC2-
related peptide (TPTGTQTPTT) conjugated to bovine serum
albumin (BSA). The wells were washed four times with PBS
(pH 7.3) containing 0.05% (w/v) Tween 20 (PBS/Tween), and the
remaining non-specific sites were blocked by the addition of 1%
BSA for 1 h. After four washes in PBS/Tween, semi-logarithmic
serial dilutions ofC595 scFv (75 jig ml-') were added at 50 jil per
well and incubated for 1 h. The plates were again washed four
times and anti-E-tag/HRPO (Pharmacia) at 1:1000 in PBS was
added, 50 jil per well, and incubated for 1 h. The plates were
washed four times in PBS/Tween. A solution of 0.033% (w/v)
2,2'-azino-bis (3-ethylbenzothiazoline-6-sulphonic acid) in 0.1 M
citrate phosphate bufferpH4.0, with 33% (v/v) hydrogen peroxide
added at 0.3 jil ml-' (ABTS substrate) was added to the wells at
100 jil per well. Analysis of colour development was performed
over a 10 minperiod using a Milenia Kinetic Analyser (Diagnostic
Products Corporation, Llanberis, UK).
Flow cytometry
Breast carcinoma T47D cells were grown in RPMI 1640 medium
in 75-cm3 tissue culture-treated flasks (Falcon) supplemented with
2 mM L-glutamine and 10% heat-inactivated fetal bovine serum.
Adherent cells were grown to subconfluence and harvested after
incubation with 0.05% (w/v) trypsin/0.02% (w/v) EDTA at 37°C.
Cells (1 x 105 cells per sample in duplicate) were transferred to a
1.5-ml Eppendorf tube and centrifuged at 10000g for 30 s. The
supernatant was removed and the pellet resuspended in 1% BSA
(w/v) in PBS and incubated on ice for 1 h. The cells were washed
three times with PBS and then resuspended in 100 jil of antibody
solutions and incubated on ice for 1 h. After three washes in PBS,
secondary antibodies were applied to each sample. Samples with
murine antibodies as the primary layer were treated with
rabbit anti-mouse Ig/FITC-conjugated antibodies (Dako, High
Wycombe, UK) (100 jl of a 1:500 dilution in PBS). Samples
containing C595 scFv were incubated with an equal amount of a
mouse anti-E-Tag antibody (Pharmacia) for 1 h on ice, washed
four times in PBS and incubated in a solution of the rabbit anti-
mouse Ig/FITC-conjugated antibody (Dako) as described above.
Samples were then washed four times in PBS and fixed in 1 ml of
0.5% formaldehyde (v/v) in PBS and analysed by FACScan
(Becton Dickinson). Relative fluorescence values were calculated
according to Schmid et al (1988).
Immunoreactivity with synthetic MUC1 peptide
C595, C595 scFv and an irrelevant IgG molecule, the anti-MUC2
monoclonal 996 (100 jil at 10jig ml-'), were added to 1:5 (v/v)
suspensions of 4B-CL Sepharose beads (0.5 ml) both with and
without peptide (CAPDTRPAPG) conjugated to them. Incubations
of antibody and fragments with the Sepharose beads were
performed as described for incubations with the cells by FACScan
analysis. After the appropriate secondary antibody layers had been
added and the beads washed in PBS, ABTS substrate solution was
added to the beads as described in the ELISA procedure (100 jl
per sample). The beads were centrifuged and the ABTS super-
natant added to a 96-well microtitre plate for end point analysis on
the Milenia Kinetic Analyser. Samples were analysed in triplicate.
Immunohistochemistry
Sequential 3-jim sections were cutfrom archival paraffin blocks of
breast and transitional cell bladder tumours, dewaxed in xylene
and rehydrated in graded alcoholic solutions. Endogenous peroxi-
dase activity was blocked with 1% hydrogen peroxide in methanol
for 10 min. Non-specific binding was blocked with normal swine
serum diluted 1:10 for 10min. Immunostaining was performed
using a semiautomated immunostainer (Shandon Sequenza). The
primary antibody was applied for 1 h. To detect scFv binding,
specimens were incubated for 1 h with mouse anti-E-Tag (1:50) in
PBS. Optimal antibody concentrations were determined by titra-
tion. Detection of antibody binding was performed using bio-
tinylated goat anti-mouse/rabbit immunoglobulins followed by
streptavidin/biotinylated horseradish peroxidase complex (Dako,
StreptABC complex/HRP duet, mouse/rabbit). Staining was
performed by addition of 0.025% diaminobenzidine (Sigma)
diluted in 0.1 M Tris buffer (pH 7.6), with hydrogen peroxide as
the substrate. Tissue sections were counterstained with haema-
toxylin, then rehydrated in graded alcohol solutions, cleared in
xylene and mounted in DPX mountant. Negative controls were
performed by omitting the primary antibody. Immunostaining was
performed without any form ofantigen retrieval.
Fluorescence quenching
Fluorescence quenching experiments were performed using both
C595 and C595 scFv against MUCI protein core-related peptides.
C595 antibody was diluted in PBS to a concentration of 0.12 jM
and C595 scFv diluted likewise to a concentration of 0.27 jM.
Peptides were diluted to 60jM. The antibody and fragment solu-
tions (2.5 ml) were filtered through a 0.2-jim membrane filter unit
(Sartorius, Gottingen, Germany) and 2 ml of these solutions
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Figure 1 Agarose gel of PCR products obtained from C595 scFv phagemid
library-infected HB2151 clones. Upper lanes contain PCR products from
clones using Si and S6 primers and lower lanes contain PCR products from
clones using 11 and 12 primers. In both cases, lane 1 contains molecular
weight standards of 2000, 1500, 1000, 750, 500, 300, 150 and 50 bp
(Sigma). Lanes 2-7 contain DNA amplified from clones 3, 17, 22, 31, 69 and
72 respectively
pipetted into a 3-ml quartz cuvette (1-cmpathlength). The solution
was excited at 290 nm and emitted light monitored at 345 nm
using a Luminescence Spectrometer LS-5 (Perkin Elmer).
Aliquots (2.5 jl) of the peptide solutions were added to the
antibody or fragment solutions until maximum fluorescence
quenching was observed. Calculations were performed according
to the method of Eisen (1964) and the results analysed by the
Scatchard method using the program InPlot (GraphPad Software,








C595 scFv assembly and expression
Insertion of C595 VH_ and VL-specific DNA in the scFv assembly
process was analysed by PCR amplification of the DNA from
phagemid-infected HB2151 E. coli clones grown on ampicillin
plates. These tests were performed using plasmid (phagemid)-
specific primers SI and S6 and C595-specific primers II and 12.
Analysis using the SI and S6 primers in a number of clones
confirmed the insertion of DNA in the Sfi1 and Not! cloning site.
These clones (numbered 3, 17, 22, 31 and 69) produced PCR prod-
ucts of approximately 950 bp in length (Figure 1, upper panel).
The size of these products is consistent with the assembly of
linked VH and VL into the phagemid vector at the SfiI and Not!
cloning site.
Infection of the ligated phagemid into HB2151 E. coli was also
reported by the presence of C595-specific DNA in these clones
using the II and I2 primers (Figure 1, lower panel). Here, clones
containing the C595 scFv-encoding DNA produce PCR products of
approximately 400 bp, which is consistent with the assembly of
linked VH and VLinto thephagemid vectorin the correct orientation.
All clones generating PCR products of a size not consistent with
the insertion of linked VH_ and VL-encoding DNA (the example
given in Figure 1 is clone 72) with SI and S6 primers failed to
produce PCR products from reactions containing II and I2
primers.
The expression of soluble recombinant scFv in those clones
containing C595 scFv-encoding inserts was analysed by SDS-
PAGE and Western blotting. The pCANTAB SE phagemid vector
uses a reporter sequence known as E-Tag to show the presence of
scFv. The positioning of the cloning site and the presence of an
Amber stop codon downstream of the E-Tag reporter sequence
means that in the non-repressor (HB2151) system, soluble recom-
binant scFvs contain the E-Tag sequence (GAPVPYPDPLEPR)
towards their C-termini. A murine antibody/HRPO conjugate
recognizing the E-Tag peptide sequence allows the presence of
expressed scFv to be visualized on Western blots. The use of this
reporter plus analysis of the product size through SDS-PAGE
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Figure 2 Affinity-purified C595 scFv as analysed by silver-stained SDS-PAGE (lanes a and b) and Western blot (lanes e and f) with molecular weight marker
values indicated on the extreme left. Lanes (c) and (d) are silver stained SDS-PAGE and Western blot analyses of unbound column waste respectively
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Table 1 C595 scFv clone 31 sequence
MA VQLQESGGG LVQPGGSLKLSCAASG FT
E - - - V-
FSSYGMSWV RQTP D KR LE LVATI NSNGGST
YYPDSVKGR FTI S RDNAKNTLYLQMSSLKS
EDTAMYYCARDRDGYDEGFDYWGPGTTVTV
S S G G G G S G G G G S G G G G S D E L T Q S P S M S A
-- ------------e Q-V-----A-- - -
SPGEKVTMTCSASSSVSYMHWYQQKSGTSP
KRWIYDTSKLASGVPARFSGSGSGTSYSLT
I SS M EAE DAATYYCQQWSSN PPTFGG RTKL
-LKRAAAG _PVPYP EG - - -
E LKRAAA GAPVPYPDPLEPRAA
Bold residues indicate CDRs. Variations from the C595 parental sequence are
presented underneath the scFv sequence. The linker sequence is indicated with
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Figure 3 ELISA of affinity-purified C595 scFv vs purified MUC1 urinary
mucin (-0-), MUC1 peptide conjugate AK-CG (), MUC2 peptide
conjugated to BSA (-{-) and casein (-U-)
reveals the presence of intact recombinant scFv. Preliminary
studies were performed whereby whole-cell extracts, periplasmic
extracts and supernatants from cultures ofclones 3, 17, 22, 31 and
69 were tested by SDS-PAGE and Western blotting for the pres-
ence of scFv. Only the clone numbered 31 expressed soluble
recombinant scFv in sufficient quantities to be revealed in the
periplasm and the supernatant by Western blotting and immuno-
staining (data not shown).
This clone was further analysed by DNA sequencing techniques
using the primers S1, S6, I1 and I2 to identify the exact DNA
sequence of the inserted C595 scFv-encoding region. Table 1
presents the translated primary sequence of the C595 scFv clone
31 and compares the relevant portions of the assembled recombi-
nant fragment with those of the parent antibody (Denton et al,
1995). The portions of the scFv representing the variable regions
are homologous with parental antibody sequences except for five
conservative changes. These differences reflect the degenerate
nature of the primers used in the RPAS PCRs and the fact that
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Figure 4 Immunoreactivity of C595 (A) and C595 scFv (B) by Sepharose
matrix ELISA. In A, signals are obtained through the incubation of samples
with: (a) blank Sepharose with anti-mouse lg/HRPO only; (b) blank
Sepharose with C595 and anti-mouse 1g/HRPO; (c) peptide Sepharose with
anti-mouse 1g/HRPO only; (d) peptide Sepharose with C595 and anti-mouse
1g/HRPO; (e) blank Sepharose with 996 and anti-mouse Ig/HRPO; and (f)
peptide Sepharose with 996 and anti-mouse 1g/HRPO. In B, signals are
obtained through the incubation of samples with: (a) blank Sepharose
with anti-E-Tag and anti-mouse 1g/HRPO; (b) blank Sepharose with C595
scFv, anti-E-Tag and anti-mouse Ig/HRPO; (c) peptide Sepharose with anti-
E-Tag and anti-mouse 1g/HRPO; and (d) peptide Sepharose with C595 scFv,
anti-E-Tag and anti-mouse 1g/HRPO
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Figure 5 Scatchard analyses of MUC1-related synthetic peptides in
solution to C595 (-) and C595 scFv (Cl) obtained through fluorescence
quenching. MUCI-related peptides consist of an immunodominant region
related peptide (APDTRPAPG), the p(1-25) peptide
(TAPPAHGVTSAPDTRPAPGSTAPPA) and larger peptides based on 3 (60
mer) and 5.25 (105 mer) repeats of the 20 amino acid repeat sequence for
the MUC1 mucin protein core. The MUC2-related peptide (TPTGTQTPTT) is
based on the tandem repeat sequence for the protein core of this mucin and
contains the epitope for the 996 antibody (TGTQ)
B
Figure 7 Serial breast tissue sections with carcinoma in situ towards the
left-hand side and micrometastatic foci towards the right-hand side of the
microphotographs, showing detection when stained with C595 (A) and C595
scFv (B)
0 1000 2000 3000 4000
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Figure 6 FACScan analysis of the binding of C595 and C595 scFv to T47D
cells. w6/32 is an anti-HLA-ABC positive control antibody, whereas 996 is a
MUC2-specific negative control antibody. Cells alone have no antibodies
added to the cells, and FITC and E-Tag+FITC represent the addition of these
antibodies as appropriate negative controls for C595 and C595 scFv
respectively
able to anneal to the cDNA template and prime the PCR. No
differences occur within the CDRs of the C595 scFv when
compared with the C595 sequence.
Purification of C595 scFv clone 31
The production ofC595 scFv clone 31 was scaled up from 50 ml per
sample to 800 ml per sample for purification of the antibody frag-
ment by peptide epitope affinity chromatography. Fractions of
column eluent were collected as described and the scFv in the eluent
was quantified spectrophotometrically from UV absorbance at
280 nm. Appropriate fractions were further analysed by SDS-PAGE
and Western blotting (Figure 2). Lanes (a) and (b) in Figure 2
report the purification of a protein identified as a single band of
approximately 30 kDa by SDS-PAGE. After Western blot analysis
of the same samples, lanes (e) and (f) show that this protein
contains the E-Tag sequence and identify it as C595 scFv. The
proteins that do not bind to the affinity column are identified in
lane (c). None of these proteins cross-react with the reagents used
in the Western blot analysis (lane d). Only a single band, repre-
senting unbound scFv, can be seen in the column waste eluent.
ELISA tests
Figure 3 illustrates the binding of affinity-purified C595 scFv
clone 31 to MUCI antigen, as well as to a MUICl-related peptide
(AK-CG) containing the RPAP epitope recognized by C595. It
does not bind to the MUC2-related peptide (TPTGTQTPTT) or to
wells blocked with casein. The reactivity of the scFv is consistent
with the binding specificities of other anti-MUC I antibodies,
against both the native mucin and peptide derivatives of the
MUCI protein core. Failure to react with the MUC2 sequence
peptide is consistent with epitope mapping data (Denton and Price,
1995) for C595 as the RPAP epitope is not present in the MUC2
peptide conjugate.
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Immunoreactivity
The immunoreactivity of both C595 antibody and C595 scFv was
further tested using a simple assay incorporating the Sepharose
affinity matrix used in the construction ofthe peptide affinity chro-
matography column. Both bound peptide (CAPDTRPAPG) and
blank Sepharose (no bound peptide) were used in this assay. Figure
4A indicates that C595 is able to bind to the peptide-linked
Sepharose but does not bind to blank Sepharose. Both the anti-
mouse secondary layer and a non-specific IgG antibody (996) do
not bind to either matrix. The same matrices were used to test the
binding ofC595 scFv (Figure 4B). Clearly, the scFv is able to bind
to the peptide CAPDTRAPAPG.
Fluorescence quenching
The results of fluorescence quenching experiments are given in
Figure 5. Scatchard analysis of C595 and C595 scFv reveal that
both whole and antibody fragments possess the capacity to bind
to different MUC1-related peptide analogues in solution, while
failing to react with the MUC2-related peptide. For those
analogues containing only one RPAP epitope, i.e. APDTRPAPG
and p(1-25), the binding affinities of C595 and C595 scFv are
similar. However, in peptide analogues containing more than one
epitope (60 mer and 105 mer), the whole antibody shows a much
higher binding capacity than the C595 scFv.
FACScan analysis of scFv binding to T47D cells
Thebinding ofwhole antibody and scFv to T47D breastcarcinoma
cells is illustrated in Figure 6. Mean fluorescence and associated
standard deviations are calculatedfrom normal distribution curves,
and these values are related to the autofluorescence of unlabelled
cells. These results indicate that C595, C595 scFv and w6/32 (a
positive control for human HLA-ABC) are capable of binding to
T47D cells. A non-specific IgG-negative control antibody (996)
does not bind to these cells, presumably because of the lack of
expression of MUC2 on the surface of the T47Ds. None of the
secondary and tertiary antibodies used in the FACScan procedure
(E-Tag and FITC) bound directly to the cells.
Immunohistochemistry
Figure 7A and B shows the ability ofboth C595 and C595 scFv to
preferentially bind to breast tumour tissue sections. The cyto-
plasmic and surface staining pattern is characteristic ofthe expres-
sion of MUCI mucins as described by Zotter et al (1988). Some
weak staining to benign breast ducts using the whole antibody is
seen in Figure 7A but is not observed for the scFv (Figure 7B).
DISCUSSION
The results presented here confirm the successful production of a
recombinant single-chain antibody fragment (scFv) retaining the
capacity to bind to MUCI mucin. Assembly of scFv, using the
antibody variable region genes and the recombinant antibody
phage system as described, produces a recombinant protein in
which the structural features that define the fine specificity of the
parent antibody for its antigen are retained. The only observed
differences in primary structure between the parent and recombi-
nant variable regions occur at the priming sites for the antibody
genes (Table 1). These reflect the presence of a degenerate primer
mixture used in the RPAS to amplify genes from many V region
gene families. The variation from the parental in the C595 scFv
clone 31 is conservative and does not occur in the complemen-
tarity determining regions. These framework substitutions have no
significant effect on antibody binding, nor does the incorporation
of the (G4S)3 linker sequence and the reporter (E-Tag) sequence at
the C-terminus. The ability to produce recombinant C595 scFv
from this vector system should afford analyses ofhow point muta-
tions in the CDRs affect antigen/antibody interactions, with partic-
ular emphasis on the CDR H3. Use ofthese manipulations and the
ability to rapidly analyse their effects on peptide antigen systems
should give valuable information on how these antibodies recog-
nize tumour cells, and these experiments are currently underway.
Analysis by FACScan and immunohistochemistry report the
ability of the scFv to bind to tumour cells. Immunohistochemical
analysis of the binding of scFv by these methods does not indicate
binding ofthis molecule to benign breast ducts, an observation seen
with the whole antibody. This may afford the preferential use ofthe
scFv over the C595 whole antibody as a diagnostic agent. However,
further immunohistochemical analyses are required to test this
proposal andtheseinvestigations arebeingpursued. Similarstaining
patterns were obtained with sections from bladdercarcinomas.
Fluorescence quenching (FQ) experiments indicate the capacity
ofthe scFv to bind to MUC1 and differentMUC1-relatedpeptides.
FQ analysis is sufficient to observe the general binding trends of
these antibodies and fragments to peptides in solution. Techniques
such as surface plasmon resonance may be used in future experi-
ments to investigate binding constants of these antibodies and
fragments on immobilized antigens and would serve to confirm the
binding trends observed with FQ. From the experimental data
presented, it is interesting to note the possible effect of avidity on
the binding capacities ofthese reagents as observed in the multiple
epitopic peptide antigens (60 and 105 mer). This may indicate that
a recombinant bivalent scFv (diabody) may prove to be a useful
reagent in a diagnostic scenario, and the production of such a
molecule is currently being pursued. However, a low-affinity
reagent may also be of some use as affinity influences the penetra-
tion ofthese reagents into solid tumours. This property allied to the
reduced size of the scFv and the penetrative advantage that this
gives (Yokota et al, 1992) may be of benefit in the treatment of
more substantial tumours.
Experiments have been performed in which intravesicular
administration of "'In-labelled C595 in patients with superficial
bladder cancer resulted in the selective accumulation of the
antibody in the tumour with a mean tumour-normal selectivity
ratio of 12:1 after 2 h. Administration ofwhole mouse antibody by
this route has been shown not to produce human anti-murine anti-
body (HAMA) responses in patients even after multiple adminis-
trations (Kunkler et al, 1995). These findings establish the basis
for extending the clinical usage of anti-MUCI monoclonal anti-
bodies as targeting agents with anti-tumour activity. A clinical trial
is presently underway to examine tumour targeting of 67Cu-
labelled C595 following intravesical administration in patients
with superficial bladdercancer (Hughes et al, 1997). This radionu-
clide emits both gamma and beta radioactivity and thus has poten-
tial use forboth diagnosis and radioimmunotherapy. The increased
tumour penetrative properties that C595 scFv may offer is
presently being examined.
Current trials are also underway whereby whole ["'In] C595 is
administered systemically. An obvious advantage of using the
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scFv to replace the whole antibody would be the decrease in
immunogenicity of the fragment over the parent molecule as well
as the pharmacokinetic advantage ofusing a smaller molecule that
has increased blood clearance times. Although still of murine
origin, a decrease in immunogenicity may allow multiple thera-
peutic doses to be administered, an obvious advantages in patient
management.
In summary, recombinant C595 scFv retains the ability to bind
to tumour cells, MUCI antigen and synthetic MUCI peptides.
This reagent, therefore, has diagnostic and therapeutic potential. It
may further prove to be a valuable tool in probing the fine speci-
ficity of antibody recognition on MUC1-positive tumour cells,
leading to a greater understanding of the immune recognition of
cancer cells.
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